Price
$96.55+8.20%Social Signal Score
Analyst Ratings
42 analystsRevenue
$2.18B+18.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ivan Tornos
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 17,000
- Beta
- 0.47
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.40
Financials
Revenue
$2.18B+18.8%Net Income
$198.30M+24.9%EBITDA
$328.00M-32.1%Free Cash Flow
$331.40M+11.9%EPS (diluted)
$1.03+32.1%Shares Outstanding (diluted)
192.80M-5.0%Operating Expenses
$1.00BCash & Debt
$410.00MReturn of Capital
$297.20MRevenue by Segment (annual)
$7.57BDividend per Share
$0.24Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.23B | $705.20M | $3.56 |
| 2024 | $7.68B | $903.80M | $4.45 |
| 2023 | $7.39B | $1.02B | $4.91 |
| 2022 | $6.94B | $231.40M | $1.10 |
| 2021 | $6.83B | $401.60M | $1.93 |
| 2020 | $6.13B | $-138.90M | $-0.67 |
| 2019 | $7.98B | $1.13B | $5.52 |
| 2018 | $7.93B | $-379.20M | $-1.86 |
| 2017 | $7.80B | $1.81B | $9.11 |
| 2016 | $7.67B | $305.90M | $1.51 |
| 2015 | $6.00B | $147.00M | $0.27 |
| 2014 | $4.67B | $720.30M | $4.26 |
| 2013 | $4.62B | $761.00M | $4.49 |
| 2012 | $4.47B | $755.00M | $4.32 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ZBH's reported EPS growth of -1.5% a year over 13 years.
- EPS in 5 years
- $3.30
- Implied price
- $82.56
- Return from $88.29
- -1.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $41.05 — -53.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -11.5% | -17.9% | -14.4% | -11.4% | -8.7% | -6.3% |
| -6.5% | -13.3% | -9.6% | -6.3% | -3.5% | -1.0% |
| -1.5% | -8.7% | -4.7% | -1.3% | 1.6% | 4.3% |
| 3.5% | -4.0% | 0.1% | 3.7% | 6.8% | 9.6% |
| 8.5% | 0.6% | 5.0% | 8.7% | 12.0% | 14.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (9)
- Newsprnewswire.com·27d ago·Neutral
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.
View source ↗ - Newszacks.com·31d ago·Neutral
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report? Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)seekingalpha·34d ago·Neutral
Zimmer Biomet: Showing Signs Of Life
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
Zimmer Biomet - Showing Signs Of Life Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.
View source ↗ - News (RSS)investing·38d ago·Neutral
Zimmer Biomet declares $0.24 quarterly dividend
View source ↗ - Newsprnewswire.com·38d ago·Neutral
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026.
View source ↗ - Newszacks.com·46d ago·Neutral
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now? ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
View source ↗ - Newszacks.com·56d ago·Positive
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsmarketbeat.com·57d ago·Negative
Zimmer Biomet Q2 Earnings Call Highlights Zimmer Biomet NYSE: ZBH reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $1.89 per share
Typical surprise +2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.07 vs $2.01beat
- Tue, Apr 28$2.09 vs $1.86beat
- Tue, Feb 10$2.42 vs $2.38beat
- Wed, Nov 5$1.90 vs $1.87beat
- Thu, Aug 7$2.07 vs $1.98beat
- Mon, May 5$1.81 vs $1.77beat
Estimates and results for ZBH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZBH officers and directors.
- Bought
- —
- Sold
- $1.5m
0 trades
5 trades
- Thornal Kevin Rsold
- Phipps Chad Fsold
- Yi Sangsold
- Yi Sangsold
- Winkler Lorisold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (20d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (37d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 8, 2025 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 10, 2025 (30d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Mar 13, 2025 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 11, 2024 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2024 (34d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (34d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (29d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.